← Back to Search

Opioid Addiction Recovery Support (OARS) for Opioid Use Disorder

N/A
Waitlist Available
Led By Steven J Shoptaw, PhD
Research Sponsored by Q2i, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Currently treating more than two patients with OUD using oral buprenorphine-naloxone product
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post (oars) intervention through to study completion, up to 10 months
Awards & highlights

Study Summary

This trial will help design a software that will improve outcomes for people with opioid use disorder and promote connectedness with clinicians.

Eligible Conditions
  • Opioid Use Disorder

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are currently treating more than two patients with opioid use disorder using a specific medication called oral buprenorphine-naloxone.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post (oars) intervention through to study completion, up to 10 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and post (oars) intervention through to study completion, up to 10 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number and result of urine screening tests for buprenorphine, opioids (heroin, synthetics, fentanyl), cocaine, methamphetamine, benzodiazepines, cannabis
Number of visits scheduled and kept with PCP
Secondary outcome measures
Number of times OARS patient mobile application initiated
Number of times OARS platform initiated by provider
Number of visits scheduled and kept with psychosocial providers
+2 more
Other outcome measures
Additional healthcare utilization by patients
Counts of services/medications received by patients
Return on Investment (ROI)

Trial Design

2Treatment groups
Active Control
Group I: Treatment as UsualActive Control1 Intervention
Data collected at baseline before OARS in conjunction with MOUD is implemented at study sites.
Group II: Opioid Addiction Recovery Support (OARS)Active Control1 Intervention
Data collected post-implementation of OARS in conjunction with medication for opioid use disorder (MOUD) at study sites.

Find a Location

Who is running the clinical trial?

Q2i, LLCLead Sponsor
3 Previous Clinical Trials
173 Total Patients Enrolled
University of California, Los AngelesOTHER
1,521 Previous Clinical Trials
10,278,792 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,446 Previous Clinical Trials
2,593,826 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~52 spots leftby Mar 2025